Lauren Mahon, MSN, FNP-BC, outlines nursing considerations with approved PARP inhibitors.
UR Medicine's Wilmot Cancer Institute | Strategic Alliance Partners
Latest from UR Medicine's Wilmot Cancer Institute
Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.
A secondary analysis of the COACH study revealed that a geriatric assessment–guided intervention increased the number of comorbidity-related discussions between patients and providers.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Managing Acute and Late Adverse Effects of Breast Cancer Radiation
2
An NP’s Perspective: Supporting Derm Toxicities in Breast Cancer as a Team
3
NGS Streamlines Biomarker Testing in Solid Tumors
4
Osimertinib/Chemo Boosts OS in EGFR+ NSCLC With Poor Prognosis
5
